Literature DB >> 18190818

LOAD: a pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack.

Dawn M Meyer1, Karen C Albright, Teresa A Allison, James C Grotta.   

Abstract

BACKGROUND: Most patients with ischemic stroke present to the emergency department beyond the approved 3-hour time window for thrombolytic or other revascularization therapies. Clopidogrel and aspirin loading is commonly used to prevent deterioration in other acute vascular occlusive events. This pilot study examined the safety of antiplatelet loading in acute ischemic stroke and transient ischemic attack.
METHODS: Forty patients with stroke or transient ischemic attack symptoms, not eligible for revascularization, received a single dose of 375 mg of clopidogrel and 325 mg of aspirin within 36 hours of stroke onset. All patients were admitted to a comprehensive stroke department and monitored for neurologic deterioration (2-point increase on National Institutes of Health stroke scale [NIHSS] score) and bleeding complications until hospital day 7 or discharge. NIHSS was performed at 24 hours postadmission and on hospital day 7 or discharge, whichever came first.
RESULTS: A total of 40 patients were loaded with 375 mg of clopidogrel and 325 mg of aspirin (mean 12 hours 32 minutes). Mean admission NIHSS score was 6. There were no cases of systemic hemorrhage or mortality. A single symptomatic intracranial hemorrhage (2.5%) was detected 43 hours posttreatment. When compared with matched control subjects, loaded patients were no more likely to experience hemorrhage and significantly less likely to experience neurologic deterioration (odds ratio 17.2; P < .002).
CONCLUSIONS: Loading with 375 mg of clopidogrel and 325 mg of aspirin appears to be safe when administered up to 36 hours after stroke and transient ischemic attack onset in this pilot study. Neurologic deterioration may be decreased and warrants further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18190818      PMCID: PMC2663572          DOI: 10.1016/j.jstrokecerebrovasdis.2007.09.006

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  9 in total

1.  Initial safety experience of abciximab and heparin for acute ischemic stroke.

Authors:  Pitchaiah Mandava; Scott D Lick; M A Rahman; Hans Langsjoen; K V Reddy; Jeffrey Nelson; Thomas A Kent
Journal:  Cerebrovasc Dis       Date:  2004-05-28       Impact factor: 2.762

2.  Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention.

Authors:  Willibald Hochholzer; Dietmar Trenk; Devine Frundi; Philipp Blanke; Benjamin Fischer; Katharina Andris; Hans-Peter Bestehorn; Heinz Joachim Büttner; Franz-Josef Neumann
Journal:  Circulation       Date:  2005-04-04       Impact factor: 29.690

3.  Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility.

Authors:  P A Barber; J Zhang; A M Demchuk; M D Hill; A M Buchan
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

4.  Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial.

Authors: 
Journal:  Stroke       Date:  2005-02-24       Impact factor: 7.914

5.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

Authors:  Marc S Sabatine; Christopher P Cannon; C Michael Gibson; Jose L López-Sendón; Gilles Montalescot; Pierre Theroux; Marc J Claeys; Frank Cools; Karen A Hill; Allan M Skene; Carolyn H McCabe; Eugene Braunwald
Journal:  N Engl J Med       Date:  2005-03-09       Impact factor: 91.245

8.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Christoph Diener; Julien Bogousslavsky; Lawrence M Brass; Claudio Cimminiello; Laszlo Csiba; Markku Kaste; Didier Leys; Jordi Matias-Guiu; Hans-Jürgen Rupprecht
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

Review 9.  Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care.

Authors:  Graeme J Hankey
Journal:  Cerebrovasc Dis       Date:  2004       Impact factor: 2.762

  9 in total
  12 in total

Review 1.  Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke.

Authors:  Shadi Yaghi; Hooman Kamel; Mitchell S V Elkind
Journal:  Neurology       Date:  2015-07-17       Impact factor: 9.910

2.  Short-term bleeding events observed with clopidogrel loading in acute ischemic stroke patients.

Authors:  Lester Y Leung; Karen C Albright; Amelia K Boehme; Joseph Tarsia; Kamal R Shah; James E Siegler; Erica M Jones; Gayle R Pletsch; Timothy M Beasley; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-03-29       Impact factor: 2.136

3.  LOAD: a pilot study of the safety of loading of aspirin & clopidogrel in acute ischaemic stroke and transient ischaemic attack. Is the loading dose of aspirin and clopidogrel a good alternative for patients with acute ischaemic stroke and TIA? How this will impact our clinical practice?

Authors:  Fauzia Nomani; Ayeesha Kamran Kamal
Journal:  J Pak Med Assoc       Date:  2013-10       Impact factor: 0.781

4.  Prevalence and clinical characteristics of intracerebral hemorrhages associated with clopidogrel.

Authors:  Steve M Cordina; Ameer E Hassan; Mustapha A Ezzeddine
Journal:  J Vasc Interv Neurol       Date:  2009-01

Review 5.  Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose.

Authors:  Tarun Girotra; Forrest Lowe; Wuwei Feng; Bruce Ovbiagele
Journal:  Curr Treat Options Neurol       Date:  2018-06-23       Impact factor: 3.598

6.  rLOAD: does sex mediate the effect of acute antiplatelet loading on stroke outcome.

Authors:  Dawn M Meyer; Jo-Ann Eastwood; M Peggy Compton; Karen Gylys; Justin A Zivin
Journal:  Biol Sex Differ       Date:  2014-07-15       Impact factor: 5.027

7.  Safety and Efficacy of Acute Clopidogrel Load in Patients with Moderate and Severe Ischemic Strokes.

Authors:  Amir Shaban; Dominique J Monlezun; Natalia Rincon; Jonathan Tiu; Melisa Valmoria; Sheryl Martin-Schild
Journal:  Stroke Res Treat       Date:  2016-10-13

8.  The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail.

Authors:  Feng-Tong Zuo; Hui Liu; Hui-Jun Wu; Na Su; Jie-Qiong Liu; Ai-Qin Dong
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

Review 9.  Minor Stroke and Transient Ischemic Attack: Research and Practice.

Authors:  Aleksandra Yakhkind; Ryan A McTaggart; Mahesh V Jayaraman; Matthew S Siket; Brian Silver; Shadi Yaghi
Journal:  Front Neurol       Date:  2016-06-10       Impact factor: 4.003

10.  Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial.

Authors:  Ying Zhao; Wanyong Yang; Zefeng Tan; Wenmin Wang; Weimin Xiao; Jinsheng Zeng; Anding Xu
Journal:  Stroke Vasc Neurol       Date:  2017-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.